People
Recently, the U.S. Centers for Disease Control and Prevention (CDC) made a regular data update on COVID-19 deaths. Unfortunately, the data, and how it was presented, was immediately misinterpreted.
When Bionano Genomics acquired Lineagen, Inc. in August, the genomic analysis company gained the final piece it needed to provide comprehensive structural variation detection for researchers and drug developers and a reimbursement pathway for clinicians who want to use its technology to replace cytogenetic tests to diagnose cancers and rare diseases.
On Sunday, U.S. Food and Drug Administration Commissioner Stephen Hahn told the Financial Times that he would potentially fast-track a COVID-19 vaccine before clinical trials are done if it was “appropriate.”
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
President Donald Trump pledged a vaccine for the novel coronavirus that causes COVID-19 would be available by the end of the year. The remarks were made during an acceptance speech for the Republican Party presidential nomination Thursday night.
When someone gets sick with COVID-19, there is a lag in an efficient immune response, giving the virus time to do significant damage before the immune system can reign in the infection.
Lasers aren’t just for directing presentations, playing tag or annoying cats. They can also serve as virus hunters.
A new, 64-page study that has not been peer-reviewed, extrapolates the number of infections that stemmed from the company’s corporate meeting held at the Marriott Long Wharf hotel in February.
“I have been criticized for remarks I made Sunday night about the benefits of convalescent plasma,” Hahn tweeted. “The criticism is entirely justified. What I should have said better is that the data show a relative risk reduction not an absolute risk reduction.”
A novel, surface enhanced Raman spectroscopy (SERS) assay that allows viral evolution and replication to be studied inside single cells.
PRESS RELEASES